Navigation Links
Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Date:12/19/2011

ACR San Antonio Breast Cancer Symposium (SABCS).  Final Phase 2 results are expected in 2012.

The Antigen Express AE37 breast cancer vaccine was also featured in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer?:(http://www.thedailybeast.com/newsweek/2011/12/11/could-this-be-the-end-of-cancer.html)." 

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
2. alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
3. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
4. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
5. 23andMe Announces Breast Cancer Initiative
6. Amoena Helps Women Re-shape Their Lives After Breast Cancer Surgery
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
9. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
10. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
11. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 Isagenix International, a ... earned three Gold, three Silver, and three Bronze Stevie® ... held in Chicago this month.The ... premier business awards program in the U.S. ... company,s strength in developing leaders, cultivating talent, creating a ...
(Date:7/1/2015)... ... ... Apex Therapeutics announced today that company CEO, David Broecker provided a company ... presentation took place on Tuesday, June 16 and provided an update on the achievement ... treatment of pancreatic cancer. A copy of the company overview can be found ...
(Date:6/30/2015)... R-Japan Co.,Ltd. obtained the license of cell processing facility under ... Ministry of Health, Labour and Welfare Kinki Bureau of Health ... fact that R- Japan received the license ... Medical Devices Agency (PMDA) on May 18, 2015 two months ... manufacturing service to medical institutions. As of November 25, 2014, ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... webinar to provide advanced scientific research into new classes of Nanoscale Graphene-based materials ... Touted as 'the wonder material of the 21st Century' by the researchers ...
Breaking Biology Technology:Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... Omthera Pharmaceuticals, Inc., a privately-held emerging ... of a randomized, open-label, four-way cross-over pharmacokinetics ... Omthera,s lead compound for the treatment of ... the leading prescription Omega-3.  Epanova is an ...
... Nov. 8, 2010 Solutia Inc. (NYSE: ... sold its Perkalink® business and entered into a ... to LANXESS, a Germany-based specialty chemicals company.   ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081029/AQW096LOGO) "The sale ...
... in Europe Could Be Prevented -- PRAGUE, November 8, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets 2Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 2Study Shows Cardiovascular Deaths in Europe Could Be Prevented 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 4Study Shows Cardiovascular Deaths in Europe Could Be Prevented 5Study Shows Cardiovascular Deaths in Europe Could Be Prevented 6Study Shows Cardiovascular Deaths in Europe Could Be Prevented 7Study Shows Cardiovascular Deaths in Europe Could Be Prevented 8Study Shows Cardiovascular Deaths in Europe Could Be Prevented 9Study Shows Cardiovascular Deaths in Europe Could Be Prevented 10
(Date:6/9/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, will be providing demonstrations of its ... 2015 Drug Information Association (DIA) Annual Meeting in ... presentations will include previews of many exciting new enhancements ... iMedNet 2015 Feature 1 Release. ...
(Date:6/8/2015)... , June 8, 2015  Trovagene, Inc. (NASDAQ: ... that clinical data featuring its Precision Cancer Monitoring SM ... and Liquid Biopsies conference in San Diego, CA ... AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy ... on June 13-16. "We continue to advance ...
(Date:6/5/2015)... GERMANTOWN, Md. , June 5, 2015  Intrexon ... synthetic biology, today announced that it has determined the ... of all of its 17,830,305 shares of ZIOPHARM Oncology, ... or about June 12, 2015, the distribution date, as ... stock, and on warrants to purchase shares of Intrexon ...
Breaking Biology News(10 mins):MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4
... and lifestyle offers significant benefits to people with chronic ... Dietitian Katrina Campbell, who graduated with her PhD ... at the Royal Brisbane and Women,s Hospital (RB&WH) and ... thesis. Dr Campbell said depending on the patient,s ...
... to manage some of Florida,s most popular sport fish, ... Effective Strategies for the Management of Sustainable Fisheries: Biology ... Ault, an assistant professor in the Division of ... has a unique high-tech tagging approach to studying tarpon ...
... PatientSecure(TM) on Display at Leading Healthcare Conference, ... 20 Identity,management in a busy healthcare ... especially when it must be repeated with ... Inc., a leading supplier of,innovative computer products, ...
Cached Biology News:Diet support helps chronic kidney patients 2New tarpon, bonefish compendium published 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 2Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 3Fujitsu and HT Systems Partner to Provide Biometric Patient Identity Management 4
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... is used as an internal standard for ... dilution mass spectrometry. 5-OxoETE is a polyunsaturated ... 5-HETE in human neutrophils. It stimulates cytosolic ... of 2 nM. 5-OxoETE selectively stimulates the ...
... The dsRNA Marker consists of ten ... 200, 300, 400, 500 and 1,000 base ... size marker for determinating sizes of double-stranded ... in the dsRNA Marker is adjusted to ...
... White to off-white solid. ... glycosylation and blocks the formation of ... vitro against Gram-positive bacteria, yeasts, ... of functional thrombin receptors on human ...
Biology Products: